BioCentury | Dec 6, 2018
Translation in Brief

Opening chromatin: long-term detriment?

An Institute for Research in Biomedicine team has shown increasing chromatin accessibility in cancer could promote tumor aggressiveness, not reduce tumor mutation burden (TMB) as previously thought. The findings, reported last month in Nature Cell...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BioCentury | Jul 21, 2017
Company News

Roche ends cancer deal with Oryzon

Roche (SIX:ROG; OTCQX:RHHBY) terminated a 2014 deal with Oryzon Genomics S.A. (Madrid:ORY) granting the pharma rights to cancer candidate ORY-1001 . Oryzon said Roche's decision was part of a portfolio reprioritization. Roche is responsible for completing...
BioCentury | Jul 20, 2017
Company News

Roche ends cancer deal with Oryzon

Oryzon Genomics S.A. (Madrid:ORY) fell €0.80 (27%) to €2.11 on Thursday after Roche (SIX:ROG;OTCQX:RHHBY) terminated a 2014 deal granting the pharma rights to cancer candidate ORY-1001 . Oryzon said Roche's decision was part of a portfolio...
BioCentury | Mar 31, 2017
Financial News

Oryzon completes private placement

On March 31, cancer and neurodegenerative disease company Oryzon Genomics S.A. (Madrid:ORY) raised €18.2 million ($19.8 million) through the sale of 5.7 million shares at €3.20 in a private placement with institutional investors. Guggenheim; Bryan,...
BioCentury | Oct 3, 2016
Financial News

Oryzon financial update

Oryzon Genomics S.A. , Barcelona, Spain Business: Cancer, Neurology, Diagnostic Date announced: 2016-09-26 Note: Oryzon raised EUR5.3 million ($6 million) in a second tranche of a debt financing, bringing the total raised in the offering to...
BioCentury | Aug 11, 2016
Distillery Therapeutics

Therapeutics: Glycogen synthase kinase 3β (GSK3B); ubiquitin specific peptidase 22 (USP22); lysine-specific demethylase 1 (LSD1; KDM1A)

Cancer INDICATION: Brain cancer Patient sample and mouse studies suggest that inhibiting the GSK3β-USP22- LSD1 axis could help treat glioblastoma multiforme (GBM) and other brain cancers. In tumor samples from GBM and astrocytoma patients, levels...
BioCentury | May 30, 2016
Company News

Oryzon, Roche deal

Oryzon and Roche extended by one year until March 2017 a collaborative research program to explore the potential of ORY-1001 in cancer and hematology indications beyond acute leukemia. The research program was included as part...
BioCentury | May 9, 2016
Financial News

Oryzon completes venture financing

Oryzon Genomics S.A. , Barcelona, Spain Business: Cancer, Neurology, Diagnostic Date completed: 2016-05-04 Type: Venture financing Raised: EUR10.5 million ($12 million) Note: The four- and five-year loans bear interest at 2-3%. WIR Staff cancer Diagnostic Neurology...
BioCentury | Feb 15, 2016
Clinical News

ORY-2001: Phase I start

Next week, Oryzon plans to begin a double-blind, Spanish Phase I trial to evaluate single and multiple ascending doses of oral ORY-2001 in 88 healthy volunteers. Oryzon Genomics S.A. , Barcelona, Spain Product: ORY-2001 Business: Neurology...
Items per page:
1 - 10 of 27
BioCentury | Dec 6, 2018
Translation in Brief

Opening chromatin: long-term detriment?

An Institute for Research in Biomedicine team has shown increasing chromatin accessibility in cancer could promote tumor aggressiveness, not reduce tumor mutation burden (TMB) as previously thought. The findings, reported last month in Nature Cell...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BioCentury | Jul 21, 2017
Company News

Roche ends cancer deal with Oryzon

Roche (SIX:ROG; OTCQX:RHHBY) terminated a 2014 deal with Oryzon Genomics S.A. (Madrid:ORY) granting the pharma rights to cancer candidate ORY-1001 . Oryzon said Roche's decision was part of a portfolio reprioritization. Roche is responsible for completing...
BioCentury | Jul 20, 2017
Company News

Roche ends cancer deal with Oryzon

Oryzon Genomics S.A. (Madrid:ORY) fell €0.80 (27%) to €2.11 on Thursday after Roche (SIX:ROG;OTCQX:RHHBY) terminated a 2014 deal granting the pharma rights to cancer candidate ORY-1001 . Oryzon said Roche's decision was part of a portfolio...
BioCentury | Mar 31, 2017
Financial News

Oryzon completes private placement

On March 31, cancer and neurodegenerative disease company Oryzon Genomics S.A. (Madrid:ORY) raised €18.2 million ($19.8 million) through the sale of 5.7 million shares at €3.20 in a private placement with institutional investors. Guggenheim; Bryan,...
BioCentury | Oct 3, 2016
Financial News

Oryzon financial update

Oryzon Genomics S.A. , Barcelona, Spain Business: Cancer, Neurology, Diagnostic Date announced: 2016-09-26 Note: Oryzon raised EUR5.3 million ($6 million) in a second tranche of a debt financing, bringing the total raised in the offering to...
BioCentury | Aug 11, 2016
Distillery Therapeutics

Therapeutics: Glycogen synthase kinase 3β (GSK3B); ubiquitin specific peptidase 22 (USP22); lysine-specific demethylase 1 (LSD1; KDM1A)

Cancer INDICATION: Brain cancer Patient sample and mouse studies suggest that inhibiting the GSK3β-USP22- LSD1 axis could help treat glioblastoma multiforme (GBM) and other brain cancers. In tumor samples from GBM and astrocytoma patients, levels...
BioCentury | May 30, 2016
Company News

Oryzon, Roche deal

Oryzon and Roche extended by one year until March 2017 a collaborative research program to explore the potential of ORY-1001 in cancer and hematology indications beyond acute leukemia. The research program was included as part...
BioCentury | May 9, 2016
Financial News

Oryzon completes venture financing

Oryzon Genomics S.A. , Barcelona, Spain Business: Cancer, Neurology, Diagnostic Date completed: 2016-05-04 Type: Venture financing Raised: EUR10.5 million ($12 million) Note: The four- and five-year loans bear interest at 2-3%. WIR Staff cancer Diagnostic Neurology...
BioCentury | Feb 15, 2016
Clinical News

ORY-2001: Phase I start

Next week, Oryzon plans to begin a double-blind, Spanish Phase I trial to evaluate single and multiple ascending doses of oral ORY-2001 in 88 healthy volunteers. Oryzon Genomics S.A. , Barcelona, Spain Product: ORY-2001 Business: Neurology...
Items per page:
1 - 10 of 27